Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Eye (Basingstoke)

Volumn 27, Issue 9, 2013, Pages 1013-1021

  Inoue, M ^a   Arakawa, A ^a   Yamane, S ^a   Kadonosono, K ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Age related macular degeneration; Intravitreal injection; Photodynamic therapy; Polypoidal choroidal vasculopathy; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CILIARY DISK; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INVOLUTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RECURRENCE RISK; REMISSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETROSPECTIVE STUDY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84883753580     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.179     Document Type: Article

References (29)

1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10(1): 1-8
2. Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997; 115(4): 478-485
3. Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T et al. Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003; 121(10): 1392-1396
4. Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I et al. Polypoidal choroidal vasculopathy: Natural history. Am J Ophthalmol 2002; 133(5): 639-648
5. Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002; 22(5): 529-535
6. Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica 2004; 218(3): 193-201
7. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series. Ophthalmology 2004; 111(8): 1576-1584
8. Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2007; 51(4): 270-277
9. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008; 115(1): 141-146
10. Rouvas AA, Papakostas TD, Ntouraki A, Douvali M, Vergados I, Ladas ID. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 2011; 31(3): 464-474
11. Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008; 146(4): 513-519
12. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011; 55(1): 39-44
13. Leal S, Silva R, Figueira J, Cachulo ML, Pires I, de Abreu Jr. et al. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: Results after 3 years of follow-up. Retina 2010; 30(8): 1197-1205
14. Lee WK, Kim KS, Kim W, Lee SB, Jeon S. Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters. Am J Ophthalmol 2012; 154(2): 355-365.e1
15. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431
16. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010; 94(3): 297-301
17. Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 2012; 154(1): 117-124.e1
18. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al. EVEREST STUDY: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32(8): 1453-1464
19. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117(10): 1329-1345
20. Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina 2010; 30(9): 1376-1385
21. Schnurrbusch UE, Welt K, Horn LC, Wiedemann P, Wolf S. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 2001; 85(9): 1086-1091
22. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44(10): 4473-4480
23. Mataix J, Desco MC, Palacios E, Garcia-Pous M, Navea A. Photodynamic therapy for age-related macular degeneration treatment: Epidemiological and clinical analysis of a long-Term study. Ophthalmic Surg Lasers Imaging 2009; 40(3): 277-284
24. Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007; 27(3): 335-341
25. Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica 2011; 226(3): 145-150
26. Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010; 150(1): 48-54. e1
27. Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 2012; 153(1): 68-80. e1
28. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2012; 32(7): 1272-1279
29. Kim M, Kim K, Kim do G, Yu SY, Kwak HW. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Ophthalmologica 2011; 226(4): 205-213